Literature DB >> 25994796

Human chorionic gonadotropin is expressed virtually in all intracranial germ cell tumors.

Hirokazu Takami1, Shintaro Fukushima, Kohei Fukuoka, Tomonari Suzuki, Takaaki Yanagisawa, Yuko Matsushita, Taishi Nakamura, Hideyuki Arita, Akitake Mukasa, Nobuhito Saito, Masayuki Kanamori, Toshihiro Kumabe, Teiji Tominaga, Keiichi Kobayashi, Motoo Nagane, Toshihiko Iuchi, Kaoru Tamura, Taketoshi Maehara, Kazuhiko Sugiyama, Mitsutoshi Nakada, Yonehiro Kanemura, Masahiro Nonaka, Kiyotaka Yokogami, Hideo Takeshima, Yoshitaka Narita, Soichiro Shibui, Yoichi Nakazato, Ryo Nishikawa, Koichi Ichimura, Masao Matsutani.   

Abstract

Human chorionic gonadotropin (hCG) production has been utilized as a diagnostic marker for germinoma with syncytiotrophoblastic giant cells (STGC) and choriocarcinoma. Elevated hCG in germinoma is considered to predict less favorable prognosis, and an intensive treatment strategy may accordingly be applied. However, there is some evidence that any germinoma may produce hCG to varying extent. We investigated mRNA expression of the hCG β subunit (hCGβ) using real time quantitative polymerase chain reaction in 94 germ cell tumors (GCTs). Most (93.3 %) GCTs showed higher expression levels compared with that of normal brain tissue (1.09 × 10(0)-1.40 × 10(5) fold). The expression was the highest in GCTs which harbor choriocarcinoma or STGC components. The expression level of hCGβ in germinoma was highly variable (1.09 × 10(0)-5.88 × 10(4) fold) in linear but not bimodal distribution. hCG concentrations in serum and CSF correlated with gene expression, especially when GCTs with single histological component were analyzed separately. The expression was not significantly associated with recurrence in pure germinoma. These results suggest that the serum/CSF hCG levels may need to be interpreted with caution as most GCTs appear to have the capacity of producing hCG irrespective of their histology. The clinical significance of ubiquitous hCG expression in GCTs needs further investigation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25994796     DOI: 10.1007/s11060-015-1809-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  30 in total

1.  Hyperglycosylated hCG, hCGβ and Hyperglycosylated hCGβ: interchangeable cancer promoters.

Authors:  Laurence A Cole; Stephen Butler
Journal:  Mol Cell Endocrinol       Date:  2011-11-12       Impact factor: 4.102

2.  CNS germinoma with elevated serum human chorionic gonadotropin level: clinical characteristics and treatment outcome.

Authors:  Hiroyuki Ogino; Yuta Shibamoto; Tsuyoshi Takanaka; Kazunori Suzuki; Shun-Ichi Ishihara; Tetsuya Yamada; Chikao Sugie; Yoshihito Nomoto; Mikio Mimura
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-01       Impact factor: 7.038

3.  Cerebral germinoma with syncytiotrophoblastic giant cells: feasibility of predicting prognosis using the serum hCG level.

Authors:  S Utsuki; N Kawano; H Oka; T Tanaka; T Suwa; K Fujii
Journal:  Acta Neurochir (Wien)       Date:  1999       Impact factor: 2.216

4.  Germinoma with malignant transformation to nongerminomatous germ cell tumor.

Authors:  Judith M Wong; Susan N Chi; Karen J Marcus; Bat-Sheva Levine; Nicole J Ullrich; Shannon MacDonald; Mirna Lechpammer; Liliana C Goumnerova
Journal:  J Neurosurg Pediatr       Date:  2010-09       Impact factor: 2.375

5.  Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study.

Authors:  Syed K Mohsin; Heidi Weiss; Thomas Havighurst; Gary M Clark; Melora Berardo; Le D Roanh; Ta V To; Zhang Qian; Zho Qian; Richard R Love; D Craig Allred
Journal:  Mod Pathol       Date:  2004-12       Impact factor: 7.842

Review 6.  Pathogenesis of intracranial germ cell tumors reconsidered.

Authors:  K Sano
Journal:  J Neurosurg       Date:  1999-02       Impact factor: 5.115

Review 7.  Intracranial germ-cell tumors: natural history and pathogenesis.

Authors:  M T Jennings; R Gelman; F Hochberg
Journal:  J Neurosurg       Date:  1985-08       Impact factor: 5.115

8.  Intracranial germ cell tumors: pathobiological and immunohistochemical aspects of 70 cases.

Authors:  J Bjornsson; B W Scheithauer; H Okazaki; R W Leech
Journal:  J Neuropathol Exp Neurol       Date:  1985-01       Impact factor: 3.685

Review 9.  Biological functions of hCG and hCG-related molecules.

Authors:  Laurence A Cole
Journal:  Reprod Biol Endocrinol       Date:  2010-08-24       Impact factor: 5.211

10.  SOX17 is a critical specifier of human primordial germ cell fate.

Authors:  Naoko Irie; Leehee Weinberger; Walfred W C Tang; Toshihiro Kobayashi; Sergey Viukov; Yair S Manor; Sabine Dietmann; Jacob H Hanna; M Azim Surani
Journal:  Cell       Date:  2014-12-24       Impact factor: 41.582

View more
  8 in total

1.  Integrated clinical, histopathological, and molecular data analysis of 190 central nervous system germ cell tumors from the iGCT Consortium.

Authors:  Hirokazu Takami; Kohei Fukuoka; Shintaro Fukushima; Taishi Nakamura; Akitake Mukasa; Nobuhito Saito; Takaaki Yanagisawa; Hideo Nakamura; Kazuhiko Sugiyama; Masayuki Kanamori; Teiji Tominaga; Taketoshi Maehara; Mitsutoshi Nakada; Yonehiro Kanemura; Akio Asai; Hideo Takeshima; Yuichi Hirose; Toshihiko Iuchi; Motoo Nagane; Koji Yoshimoto; Akira Matsumura; Kazuhiko Kurozumi; Hiroyuki Nakase; Keiichi Sakai; Tsutomu Tokuyama; Soichiro Shibui; Yoichi Nakazato; Yoshitaka Narita; Ryo Nishikawa; Masao Matsutani; Koichi Ichimura
Journal:  Neuro Oncol       Date:  2019-12-17       Impact factor: 12.300

2.  Significance of human chorionic gonadotropin as a predictor of resistance to standard chemo-radiotherapy for pure germinoma.

Authors:  Akihiro Inoue; Takanori Ohnishi; Shohei Kohno; Shiro Ohue; Shinji Iwata; Shirabe Matsumoto; Masahiro Nishikawa; Saya Ozaki; Yawara Nakamura; Yosuke Mizuno; Riko Kitazawa; Takeharu Kunieda
Journal:  Neurosurg Rev       Date:  2017-08-18       Impact factor: 3.042

3.  Outcomes of intracranial non-germinomatous germ cell tumors: a retrospective Asian multinational study on treatment strategies and prognostic factors.

Authors:  Kyung Taek Hong; Jung Woo Han; Enrica Ee Kar Tan; Tai-Tong Wong; Joo-Young Kim; Hiroshi Fuji; Hwa Kyung Byun; Kyung-Nam Koh; Ru Xin Wong; Hsin-Lun Lee; Hong In Yoon; Joo Ho Lee; Ji Hoon Phi; Seung-Ki Kim; Dong-Seok Kim; Chuhl Joo Lyu; Jung Yoon Choi; Hyoung Jin Kang; Yi-Wei Chen; Yi-Yen Lee; Ho Joon Im; Young-Shin Ra; Seung Do Ahn; Sharon Yin Yee Low; Wen Shen Looi; Hyeon Jin Park; Yang-Gun Suh; Chang-Ok Suh; Kyu-Chang Wang
Journal:  J Neurooncol       Date:  2022-08-31       Impact factor: 4.506

4.  Roles of Tumor Markers in Central Nervous System Germ Cell Tumors Revisited with Histopathology-Proven Cases in a Large International Cohort.

Authors:  Hirokazu Takami; Christopher S Graffeo; Avital Perry; Caterina Giannini; Yoichi Nakazato; Nobuhito Saito; Masao Matsutani; Ryo Nishikawa; Koichi Ichimura; David J Daniels
Journal:  Cancers (Basel)       Date:  2022-02-15       Impact factor: 6.639

5.  Solitary Langerhans cell histiocytosis located in the neurohypophysis with a positive titer HCG-β in the cerebrospinal fluid.

Authors:  Yasuyuki Kinoshita; Fumiyuki Yamasaki; Satoshi Usui; Vishwa Jeet Amatya; Atsushi Tominaga; Kazuhiko Sugiyama; Kaoru Kurisu
Journal:  Childs Nerv Syst       Date:  2015-11-02       Impact factor: 1.475

Review 6.  Advances in Molecular Profiling and Developing Clinical Trials of CNS Germ Cell Tumors: Present and Future Directions.

Authors:  Hirokazu Takami
Journal:  Curr Oncol Rep       Date:  2022-01-20       Impact factor: 5.075

7.  Value of C-11 methionine PET/CT in patients with intracranial germinoma.

Authors:  Yong-Jin Park; Ji Won Lee; Hee Won Cho; Yearn Seong Choe; Kyung-Han Lee; Joon Young Choi; Ki Woong Sung; Seung Hwan Moon
Journal:  PLoS One       Date:  2022-02-07       Impact factor: 3.240

Review 8.  Biomarkers for risk-based treatment modifications for CNS germ cell tumors: Updates on biological underpinnings, clinical trials, and future directions.

Authors:  Hirokazu Takami; Koichi Ichimura
Journal:  Front Oncol       Date:  2022-09-05       Impact factor: 5.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.